Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sandoz Group Ag (SDZNY)

Sandoz Group Ag (SDZNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 20,746,880
  • Shares Outstanding, K 440,000
  • Annual Sales, $ 10,384 M
  • Annual Income, $ 1,000 K
  • EBIT $ 0 M
  • EBITDA $ 307 M
  • 60-Month Beta 0.39
  • Price/Sales 1.99
  • Price/Cash Flow 17.51
  • Price/Book 2.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/04/25 [--]
  • Annual Dividend & Yield 0.41 (0.86%)
  • Most Recent Dividend 0.405 on 04/22/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.0600 +26.43%
on 04/22/25
48.3101 -0.39%
on 05/20/25
+7.8800 (+19.58%)
since 04/17/25
3-Month
35.6100 +35.13%
on 04/07/25
48.3101 -0.39%
on 05/20/25
+1.1901 (+2.54%)
since 02/20/25
52-Week
34.5000 +39.48%
on 05/29/24
49.8099 -3.39%
on 02/14/25
+12.9200 (+36.70%)
since 05/20/24

Most Recent Stories

More News
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 48.1200 (+2.05%)
RDY : 14.50 (+0.28%)
TEVA : 16.78 (-1.41%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 48.1200 (+2.05%)
RDY : 14.50 (+0.28%)
TEVA : 16.78 (-1.41%)
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash,...

ITCI : 131.87 (-0.04%)
SDZNY : 48.1200 (+2.05%)
JNJ : 153.66 (+0.77%)
Why Coherus Biosciences Popped Today

Coherus is divesting its non-core ophthalmology franchise.

SDZNY : 48.1200 (+2.05%)
CHRS : 0.8200 (+2.50%)
Eli Lilly, McKesson, Novartis Flash Promising Chart Action

Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.

MCK : 719.19 (-0.99%)
SDZNY : 48.1200 (+2.05%)
COR : 292.93 (+0.10%)
LLY : 747.01 (-1.07%)
NVS : 112.28 (+1.42%)
CAH : 154.77 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Sandoz Group AG develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars and biotechnology manufacturing services and anti-infectives, such as active pharmaceutical...

See More

Key Turning Points

3rd Resistance Point 48.9302
2nd Resistance Point 48.6201
1st Resistance Point 48.3701
Last Price 48.1200
1st Support Level 47.8100
2nd Support Level 47.4999
3rd Support Level 47.2499

See More

52-Week High 49.8099
Last Price 48.1200
Fibonacci 61.8% 43.9615
Fibonacci 50% 42.1549
Fibonacci 38.2% 40.3484
52-Week Low 34.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar